Clinical Trial Update: Positron Emission Tomography (PET) Study With [11C]Raclopride to Determine Central D2 Dopamine Occupancy of SEROQUEL [Phase 1]

View source ↗

Summary

Phase 1 PET imaging study to assess central D2 dopamine receptor occupancy by quetiapine (SEROQUEL) in depression; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder

Drugs mentioned

• SEROQUEL (QUETIAPINE)

Snippet

Sponsor: AstraZeneca | Conditions: Depression | Phase 1 | Status: COMPLETED